Establishment of the removal method of undifferentiated induced pluripotent stem cells coexisting with chondrocytes using R-17F antibody

Regen Med. 2022 Nov;17(11):793-803. doi: 10.2217/rme-2022-0010. Epub 2022 Sep 26.

Abstract

Aim: Tumorigenicity of residual undifferentiated induced pluripotent stem cells (iPSCs) is a major concern. The purpose of this study was to investigate the optimal conditions for removal of iPSCs using R-17F antibody, which recognizes specific glycosphingolipids glycans on undifferentiated iPSCs and exhibits selective cytotoxicity to iPSCs. Materials & methods: After adding of R-17F and secondary antibody to co-cultured iPSCs and chondrocytes, residual iPSCs were quantitatively evaluated by iPS specific glycome analysis. Results: Undifferentiated iPSCs were sufficiently removed using R-17F in combination with an equal amount of a secondary antibody. Furthermore, teratomas were not observed upon transplantation of co-cultured cells pretreated under the same conditions into testes of immunodeficient mice. Conclusion: This removal method incorporating R-17F may be useful for regenerative medicine using iPSCs.

Keywords: R-17F; antibody; chondrocytes; cytotoxicity; glycosphingolipids; induced pluripotent stem cells; secondary antibody; teratoma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies
  • Cell Differentiation
  • Chondrocytes
  • Glycosphingolipids
  • Induced Pluripotent Stem Cells*
  • Mice
  • Teratoma*

Substances

  • Antibodies
  • Glycosphingolipids